Panion & BF Biotech Inc. AI Stock Analysis
Panion & BF Biotech Inc. (1760) AI Stock Analysis
Panion & BF Biotech Inc.
(TWSE:1760)
Panion & BF Biotech scores moderately well, anchored by improving financial performance: record profitability, expanding margins and a de-levered balance sheet with debt-to-equity of just 0.33. Valuation support comes from a moderate 19.5x P/E, a 4.09% dividend yield and low volatility (beta 0.29). The score is held back by weak technicals, with the price below all major moving averages and negative MACD momentum, alongside fundamental concerns around a stalled top line, declining operating and free cash flow, and a single-digit return on equity. A renewed return to revenue growth and better cash conversion would be needed for a materially higher rating.
Panion & BF Biotech Inc. (1760) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 4.13B
- Dividend Yield
- 4.19%
- Average Volume (3M)
- 117.43K
- Price to Earnings (P/E)
- 24.7
- Beta (1Y)
- 0.28
- Revenue Growth
- 1.43%
- EPS Growth
- -5.24%
- Country
- TW
- Employees
- 321
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Pharmaceuticals
Panion & BF Biotech Inc. Business Overview & Revenue Model
Company Description
Panion & Bf Biotech Inc. is a biopharmaceutical firm operating in Taiwan, engaged in the production and distribution of a diverse range of pharmaceutical goods. Its offerings cater to several key therapeutic and wellness segments, including medical a...
Panion & BF Biotech Inc. Financial Statement Overview
Summary
A solid, conservatively financed profile. The balance sheet is the standout (score 74): debt-to-equity has fallen to 0.33 from 1.0 in 2020, with equity funding roughly 61% of assets. The income statement (score 71) shows the most profitable year in the period, with net income up 53% to NT$190 million and margins expanding at the gross, operating and net level. Cash flow is the weak link (score 62): operating cash flow fell to NT$299 million from NT$351 million and free cash flow slipped 11% to NT$150 million, with capex absorbing about half of operating cash. Offsetting the profitability gains are a flat top line still below the 2022 peak and a single-digit return on equity of 9.7%.
Income Statement
71PositiveBalance Sheet
74PositiveCash Flow
62Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.11B | 2.06B | 2.03B | 1.88B | 2.40B | 1.90B |
| Gross Profit | 1.11B | 1.12B | 1.07B | 974.40M | 1.32B | 912.14M |
| EBITDA | 466.16M | 446.27M | 405.32M | 327.22M | 504.62M | 343.05M |
| Net Income | 214.82M | 190.17M | 124.52M | 77.22M | 182.34M | 104.40M |
Balance Sheet | ||||||
| Total Assets | 3.22B | 3.23B | 3.21B | 3.24B | 3.09B | 2.95B |
| Cash, Cash Equivalents and Short-Term Investments | 471.42M | 460.32M | 558.37M | 534.63M | 464.26M | 348.89M |
| Total Debt | 603.26M | 647.70M | 704.86M | 727.83M | 482.33M | 502.56M |
| Total Liabilities | 1.35B | 1.27B | 1.29B | 1.32B | 1.09B | 1.02B |
| Stockholders Equity | 1.87B | 1.95B | 1.92B | 1.91B | 2.01B | 1.93B |
Cash Flow | ||||||
| Free Cash Flow | 188.95M | 150.37M | 165.49M | -3.81M | 291.23M | 231.22M |
| Operating Cash Flow | 333.17M | 298.71M | 351.19M | 177.42M | 489.87M | 401.23M |
| Investing Cash Flow | -154.40M | -133.37M | -158.77M | -155.27M | -144.47M | -215.05M |
| Financing Cash Flow | -232.44M | -262.85M | -170.51M | 48.67M | -167.39M | -217.76M |
Panion & BF Biotech Inc. Peers Comparison
Overall Rating
- TW:176064Neutral
TW:317642Neutral
TW:472635Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:1760 | 64Neutral | TWD 4.23B | 24.71 | ― | 4.19% | 1.43% | -5.24% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:3176 | 42Neutral | TWD 4.62B | -16.65 | ― | ― | 1.11% | -94.39% |
| TW:4726 | 35Underperform | TWD 4.76B | -12.16 | ― | ― | 52.81% | 38.53% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:1760 | Panion & BF Biotech Inc. | 47.70 | -16.06 | -25.18% | |
| TW:1271 | SunWay Biotech Co., Ltd. | 58.80 | -3.76 | -6.01% | |
| TW:3176 | Medigen Biotechnology Corporation | 30.10 | 0.20 | 0.67% | |
| TW:4726 | Mycenax Biotech Inc. | 22.40 | -11.25 | -33.43% | |
| TW:6610 | TWi Biotechnology, Inc | 17.50 | -19.34 | -52.50% | |
| TW:6634 | Sinew Pharma, Inc. | 63.20 | 22.70 | 56.05% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026